The business has its proprietary technology that is referred to as iSPERSE. Using this technology platform, the company was able to create highly advanced therapeutics that would dramatically impact patient outcomes. The flagship product of the company is the PUR1900 which is currently in its clinical trial for fungal infections. This medication is created to treat pulmonary disorders of patients with compromised immune systems and those with cystic fibrosis. Another product of the company, the PUR0200 is on clinical trial for chronic obstructive pulmonary diseases (COPD).
Pulmatrix, Inc. is based in Lexington, Massachusetts. The business publicly trades on the NASDAQ and markets its shares using the symbol PULM. It is listed as one of the components of the Wilshire 5000 Index.